Clinical trials: SARS-CoV-2 Infection
COVID-19
INB03 for the Treatment of Pulmonary Complications From COVID-19
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
- Trial name
- NCT04370236
- Testing
- INB03
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- Inmune Bio, Inc.
Covid19
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
VBI-2902a and VBI-2905a are investigational vaccine candidates that use enveloped virus-like particle (eVLP) expression of a modified version of the SARS-CoV-2 spike (S) glycoprotein and are designed to induce neutralizing…
- Trial name
- NCT04773665
- Testing
- VBI-2902a, VBI-2905a
- Where
- 4 sites in Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
COVID-19
Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen
This is a Phase 2 randomized study to evaluate the safety and efficacy of IV Ampion in improving the clinical course and outcomes of adult COVID-19 patients requiring supplemental oxygen.
- Trial name
- NCT04839965
- Testing
- Ampion, Saline
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ampio Pharmaceuticals. Inc.
Myocarditis, Pericarditis
A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
The main goal of this study is to describe the clinical course, outcomes and risk factors for myocarditis and pericarditis associated with Moderna vaccination targeting SARS-CoV-2.
- Trial name
- NCT06113692
- Testing
- mRNA-1273
- Where
- 5 sites in Denmark, Norway and 2 more
- Volunteers
- 1,169 people
- Sponsor
- ModernaTX, Inc.
COVID-19
A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing
The negative global consequences of the COVID-19 pandemic has prompted efforts to develop efficient laboratory testing protocols that can be quickly scaled in a practical way.
- Trial name
- NCT04537572
- Testing
- comparison of sample collection methods
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Salveo Diagnostics
Covid19, SARS-CoV2 Infection
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
- Conditions
- Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019
- Trial name
- NCT05047783
- Testing
- Masitinib Mesylate
- Where
- 6 sites in France, Russia and 1 more
- Volunteers
- 78 people
- Sponsor
- AB Science
SARS-CoV-2 Infection, COVID-19
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.
- Trial name
- NCT04368728
- Testing
- BNT162b1, BNT162b2, BNT162b2SA
- Where
- 175 sites in United States, Argentina and 4 more
- Volunteers
- 46,969 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, SARS-CoV-2 Infection
Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has negatively impacted global health and requires more research to develop better tests and to improve disease treatment.
- Trial name
- SARS-CoV-2 (NCT04465981)
- Testing
- Sampling
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- INanoBio Inc.
COVID19, Sars-Cov-2
The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus
COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein.
- Trial name
- COV2NOSE (NCT06851611)
- Testing
- COVID-19 vaccine, low dose level, COVID-19 vaccine, high dose level, Nasal Drops
- Where
- Finland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy
COVID-19, Chronic Bronchitis
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD
Evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated COVID-19 vaccine .
- Conditions
- COVID-19, Chronic Bronchitis, COPD
- Trial name
- NCT05104216
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
SARS-CoV-2
A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults
This study is a Phase I/II clinical study in healthy adults designed to assess the safety, tolerability, and immunogenicity of receiving 2 IM injections of Covigenix VAX-001/-1b, 28 days apart.
- Trial name
- NCT04591184
- Testing
- Covigenix VAX-001
- Where
- 4 sites in Burkina Faso, Canada and 2 more
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Entos Pharmaceuticals Inc.
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
COVID-19
A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
This Phase Ⅱ/Ⅲ study is to evaluate whether or not there is a difference in time recovery of COVID-19 signs and symptoms through Day 29 between SIM0417/ritonavir and placebo.
- Trial name
- NCT05506176
- Testing
- SIM0417
- Where
- 35 sites in China
- Volunteers
- 1,208 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
COVID
Niclosamide In Moderate COVID-19
This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.
- Trial name
- NCT04436458
- Testing
- Niclosamide Oral Tablet
- Sponsor
- Entero Therapeutics
SARS-CoV-2 Infection, COVID-19
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
Substudy A: The study will evaluate the safety, tolerability, and efficacy of a booster dose of BNT162b2 when administered to participants having previously received 2 doses of BNT162b2 at least 6 months prior to randomization.
- Trial name
- NCT04955626
- Testing
- BNT162b2, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI
- Where
- 154 sites in United States, Brazil and 3 more
- Volunteers
- 16,372 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Post-COVID-19
To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19
This trial was a randomized, double-blind, placebo-controlled, loading phase III clinical study.
- Trial name
- NCT05813587
- Testing
- Meplazumab for injection, Normal saline
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19
Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults
This is an adaptive Phase I-II trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
- Trial name
- NCT04386252
- Testing
- AV-COVID-19
- Volunteers
- healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
Covid19
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with COVID-19 with gastrointestinal infection.
- Trial name
- RESERVOIR (NCT04858425)
- Testing
- Niclosamide
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 166 people
- Sponsor
- Entero Therapeutics
Covid19
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and…
- Trial name
- NCT04732468
- Testing
- hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.